Out-licensing deals by South Korean companies picked up speed in 2018 after relative sluggishness in the past couple of years. Large out-licensing transactions by biotechs noticeably increased, reflecting moves by Korean ventures to step up efforts to find global partners and that their new drug R&D expertise is being more globally recognized.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?